# Siemens Healthineers account plan

> Siemens Healthineers is a Munich-based medtech group in imaging, cancer care and diagnostics with €23,375 million FY2025 revenue and about 74,000 staff.

## At a glance

Siemens Healthineers develops, manufactures and sells imaging systems, radiotherapy and cancer-care equipment, image-guided therapy systems and in-vitro diagnostics to hospitals, laboratories, clinics, universities and research institutes. It is directly represented in more than 70 countries and sells in more than 180, with main production and development sites in Germany, the United States, India, China, Great Britain, the Republic of Korea and Slovakia. In FY2025 (year to 30 September 2025) revenue was €23,375 million, adjusted EBIT €3,855 million (margin 16.5%) and net income €2,168 million, with about 74,000 employees. The parent is registered in Munich and Siemens AG is the majority shareholder; on November 12, 2025 Siemens AG announced its intention to deconsolidate the group, preferably by a direct spin-off of 30% of the shares.

## Business units

- **Imaging** (about 56% of FY2025 revenue (€13,182 million)): Magnetic resonance, computed tomography, X-ray and molecular imaging systems, shared software and a large services business. FY2025 comparable growth was 8.5% with an adjusted EBIT margin of 20.7%; photon-counting CT is roughly 30% of CT equipment order volume and the US radiopharmaceuticals business is surpassing USD 1 billion this year.
- **Precision Therapy (Varian, Advanced Therapies, Ultrasound)** (€1,749 million in Q3 FY2026): Formed on October 1, 2025 from Varian (radiotherapy, radiosurgery, oncology software; €4,081 million in FY2025), Advanced Therapies (angiography, mobile C-arms; €2,128 million in FY2025) and Ultrasound. It is the fastest-growing segment, up 9.2% comparable in Q3 FY2026 with a margin of 17.5%.
- **Diagnostics** (about 19% of FY2025 revenue (€4,347 million)): In-vitro diagnostics for central laboratory, specialty laboratory and point-of-care, built around the Atellica line. Revenue fell 5.5% comparable in Q3 FY2026 with a 4.1% margin, hit by the structural market change in China and legacy platforms tailing off; management says it is to pursue its own strategy and its own independent structure.

## Strategic priorities

- **Elevating Health Globally strategy**: The FY2026-FY2030 strategy replaces New Ambition and is built on Patient Twinning, Precision Therapy and Healthcare AI, with a clinical focus on neurodegenerative disease, cardiovascular disease, stroke and cancer.
- **Mid-term growth targets 2027-2030**: Group comparable sales growth of 5-7% a year with double-digit adjusted EPS growth; 6-9% comparable growth in Imaging and Precision Therapy, Precision Therapy margins up about 100 basis points a year, and Diagnostics growing into the mid-single digits with mid-teens margins.
- **Value Partnerships with health systems**: The group counts more than 200 Value Partnerships and an order book worth six billion euros; new US partnerships with Cleveland Clinic and Vanderbilt Health in Q3 FY2026 amount to several hundred million euros of equipment orders.
- **Diagnostics transformation and separation**: Cost reductions from the transformation program lifted the FY2025 Diagnostics margin to 7.7%, and the unit is to move towards its own independent structure; separation costs would be treated as a portfolio measure.
- **Growth countries**: The business in newly industrialized countries already generates sales above three billion euros with double-digit growth, according to the CEO.
- **Deconsolidation from Siemens AG**: Preparations for the deconsolidation are well advanced, earliest in April next year, with recurring separation costs of about €50 million and refinancing of Siemens Group loans and talks on shared services and IT on track.

## Latest results

In Q3 FY2026 (April-June 2026) revenue was €5,764 million, up 2.8% comparable against a strong prior-year quarter, and equipment book-to-bill reached 1.27. Adjusted EBIT rose to €1,101 million (margin 19.1% vs 16.8%), lifted by refunds of US IEEPA tariffs; before refunds the group margin was 15.4%. Net income was €676 million (+21.7%) and free cash flow €1,023 million. China revenue fell 10.3% comparable to €576 million. For FY2026 the group cut its comparable revenue growth outlook to 3.5%-4.0% because of Diagnostics and raised adjusted basic EPS guidance to €2.35-€2.45.

## Investments and deals

- **Molecular imaging acquisition**: Acquired Advanced Accelerator Applications Molecular Imaging (control from December 2, 2024), extending the PETNET radiopharmaceutical network from the US into Europe; a new radiopharmacy in the UK is the first step in Europe.
- **Manufacturing sites**: A superconducting-magnet plant in Oxford, a crystal-growing factory for semiconductor production in Forchheim and a customer experience center in Charlotte.
- **R&D**: R&D expenses were €1,958 million in FY2025 (R&D intensity 8%), with more than 13,000 R&D employees and the SHIFT innovation platform with centers in Erlangen, Shanghai and Bengaluru.
- **Diagnostics portfolio renewal**: Capex on Atellica development and renewal of blood gas and urinalysis; Atellica Forte launched at ADLM with 24 assays, and a brain-health biomarker menu is being built.
- **Tariff mitigation**: A €400 million tariff impact is to be mitigated by 2028, back-end loaded.

## Challenges and risks

- **Diagnostics decline in China**: Diagnostics market volume in China is down by about 40% versus two years ago on volume-based procurement and price controls; China is now about 10% of group revenue.
- **Tariffs and trade**: Higher tariffs hit margins in all segments in FY2025, and in September 2025 the US launched a Section 232 investigation into medical technology product categories.
- **Competition**: Named competitors include GE HealthCare, Philips and United Imaging Healthcare in Imaging and Roche Diagnostics, Abbott Laboratories and Danaher in Diagnostics, alongside growing Chinese competitors, IT companies and AI start-ups.
- **Cybersecurity**: The annual report names a high threat level in healthcare, ransomware against providers and NIS2 regulation among top risks.
- **Supply-chain inflation and financing**: Inflation in memory chips, tungsten and logistics roughly offsets tariff mitigation in FY2027, and most Siemens Group loans carry change-of-control provisions ahead of the deconsolidation.

## What leadership says

> "We showed great order momentum. Our synergetic core was robust on both top and bottom lines." — Bernd Montag, Chief Executive Officer, Q3 FY2026 earnings release, July 31, 2026

> "We are the partner of choice for the design of entire healthcare systems." — Bernd Montag, Chief Executive Officer, Speech at the Annual Shareholders' Meeting, February 5, 2026

> "The next step is now for Diagnostics to consistently pursue own strategy – and derived from that, its own independent structure." — Bernd Montag, Chief Executive Officer, Speech at the Annual Shareholders' Meeting, February 5, 2026

> "the final step in a journey that started with our legal separation 10 years ago" — Bernd Montag, Chief Executive Officer, Q3 FY2026 earnings call, July 31, 2026, on the Siemens AG deconsolidation


## Where a supplier can help

- **Separation services and IT**: The deconsolidation from Siemens AG requires refinancing and new arrangements for shared services and IT, an opening for IT, finance and shared-service providers.
- **Diagnostics cost and carve-out support**: The Diagnostics transformation and move to an independent structure create demand for restructuring, operations and separation expertise.
- **Supply chain and tariff mitigation**: The €400 million tariff mitigation plan and inflation in memory chips, tungsten and logistics point to sourcing, localization and logistics suppliers.
- **Healthcare AI and cybersecurity**: Healthcare AI is one leg of the strategy and cybersecurity is a named top risk, relevant to AI, software and security vendors.
- **Manufacturing capacity ramp**: Site readiness lagged DryCool MR output and the new Varian platform will at first deliver less than market demand, pointing to installation, automation and production-capacity partners.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report 2025 (fiscal year ended 30 September 2025)](https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf)

Annual report · 2025-11-26

- Siemens Healthineers is a global medtech group (imaging, in-vitro diagnostics, cancer care, image-guided therapy) with about 74,000 employees, direct presence in more than 70 countries and sales to healthcare providers in more than 180 countries; Siemens AG is the majority shareholder.
- FY2025 revenue €23,375 million, up 4.5% nominal and 5.9% comparable; adjusted EBIT €3,855 million (margin 16.5% vs 15.7%); net income €2,168 million (+11%); adjusted basic EPS €2.39 (vs €2.23); free cash flow €2,714 million (vs €2,130 million). Proposed dividend €1.00 per share.
- Segments in FY2025: Imaging €13,182 million (+8.5% comparable, margin 20.7%), Diagnostics €4,347 million (+0.4%, margin 7.7%), Varian €4,081 million (+6.9%, margin 17.2%), Advanced Therapies €2,128 million (+4.2%, margin 15.3%). Equipment book-to-bill 1.14.
- Americas is the largest region (€10,283 million, +11.7% comparable; United States €8,904 million, +12.6%); China €2,482 million (−0.9%), with Diagnostics in China down in the low double digits on volume-based procurement.
- From FY2026 the "Elevating Health Globally" strategy (FY2026-FY2030) replaces "New Ambition"; segments become Imaging, Precision Therapy (Varian + Advanced Therapies + Ultrasound) and Diagnostics. Strategic triangle: Patient Twinning, Precision Therapy, Healthcare AI; clinical focus on neurodegenerative, cardiovascular, stroke and cancer.
- FY2026 outlook: comparable revenue growth 5% to 6% and adjusted basic EPS €2.20 to €2.40, with a significant negative currency effect; Diagnostics assumed flat.
- Higher tariffs hit margins in all segments in FY2025; top risks named are economic, political and geopolitical developments, cybersecurity and the competitive environment (including growing Chinese competitors).
- Subsequent event: on November 12, 2025 Siemens AG announced it intends to deconsolidate Siemens Healthineers and transfer 30% of the shares, preferably via a direct spin-off to Siemens AG shareholders; most of the group's debt is loans from the Siemens Group.

### [Q3 FY2026 Earnings Release and Financial Results (quarter to 30 June 2026)](https://corporate.webassets.siemens-healthineers.com/2637d4a46dbcd161/a3335cc16ed1/siemens-healthineers-Q3_FY2026_Earnings-Release-and-Financial-Results.pdf)

Interim report · 2026-07-31

- Q3 FY2026 revenue €5,764 million, +2.8% comparable (+1.8% nominal) against a very strong prior-year quarter (7.6%); equipment book-to-bill an outstanding 1.27.
- Adjusted EBIT €1,101 million, margin 19.1% (16.8% a year earlier), lifted in all segments by refunds of tariffs imposed under the US IEEPA; net income €676 million (+21.7%); adjusted basic EPS €0.70 (€0.64).
- Free cash flow €1,023 million, including around €0.2 billion of tariff refunds.
- Imaging €3,008 million, +2.3% comparable, margin 26.5%; Precision Therapy €1,749 million, +9.2%, margin 17.5% (Varian €1,052 million, +9.3%); Diagnostics €992 million, −5.5%, margin 4.1%.
- China revenue €576 million, −10.3% comparable; EMEA +7.3%, Americas +3.1%. Diagnostics fell sharply in China on a structural market change.
- Nine months: revenue €16,846 million, +3.2% comparable.
- FY2026 outlook cut for revenue to 3.5%-4.0% comparable growth (from 4.5%-5.0%) because of Diagnostics, and raised for adjusted basic EPS to €2.35-€2.45 (from €2.20-€2.30) on the tariff refunds.

### [Q3 FY2026 earnings call transcript - Bernd Montag (CEO) and Jochen Schmitz (CFO)](https://corporate.webassets.siemens-healthineers.com/91e2e22c76fbf662/beca9eeb382f/siemens-healthineers-Q3_FY2026_Analyst-call-transcript.pdf)

Executive talk · Bernd Montag, Chief Executive Officer (with Jochen Schmitz, Chief Financial Officer) · 2026-07-31

- Montag: outstanding Q3 equipment book-to-bill of 1.27, about 1.17 excluding Value Partnerships; two new US partnerships (Cleveland Clinic, Vanderbilt Health) together worth several hundred million euros of equipment orders.
- The "Synergetic core" (Imaging and Precision Therapy) grew 5%; Precision Therapy 9%; Imaging soft against 12% comparables, with about €75-80 million of revenue shifted to Q4 because site readiness lagged factory output of DryCool MR systems.
- Photon-counting CT is now roughly 30% of CT equipment order volume and has lifted US CT share; DryCool is half of MR units ordered; the US radiopharmaceuticals business is surpassing USD 1 billion this year.
- Diagnostics keeps declining on China's market rebasing (market volume "down by about 40%" versus two years ago) and legacy platforms tailing off; Atellica Forte launched at ADLM. China is now about 10% of group revenue.
- Tariff refunds added about €0.15 to EPS; margins ex-refunds: Imaging 21.6%, Precision Therapy 14.1%, group 15.4%. Net debt cut by around €800 million to around €12 billion; leverage 2.8x.
- Deconsolidation by Siemens AG: preparations well advanced; earliest in April next year; recurring separation costs of a mid-double-digit million amount and no branding fee expected.
- FY2027 baseline: €2.25 adjusted EPS (FY2026 guide without refunds), growth from there; supply-chain inflation (memory chips, tungsten, logistics) roughly offsets the ramp of the €400 million tariff mitigation.

### [Speech at the Annual Shareholders' Meeting 2026 - Bernd Montag, CEO](https://corporate.webassets.siemens-healthineers.com/56a7d9dd2c73d722/4496fd49d980/siemens-healthineers-asm-2026-Speech-CEO.pdf)

Executive talk · Bernd Montag, Chief Executive Officer · 2026-02-05

- 2026 marks the start of the "Elevating Health Globally" strategy phase and, after a potential deconsolidation by Siemens AG, the aim to be "an attractive investment for more shareholders than ever before"; timing and form of the spin-off are for Siemens AG to decide.
- Claims number one worldwide in imaging and precision therapy, systems in 90 percent of leading clinics, more than 700,000 systems in use, R&D spending in the region of two billion euros.
- More than 200 Value Partnerships; order book worth six billion euros; Alberta partnership worth 800 million Canadian dollars over eight years.
- Varian merger "a resounding success": its market share grew by ten percentage points to over 60 percent in five years.
- Imaging and Precision Therapy form the synergetic core; Diagnostics, with few synergies, is to pursue its own strategy and "its own independent structure".
- Mid-term targets 2027-2030: 6-9% comparable growth in Imaging and Precision Therapy, Precision Therapy margins up about 100 basis points a year, Diagnostics to mid-single-digit growth and mid-teens margins; group 5-7% comparable growth a year with double-digit adjusted EPS growth.
- Q1 FY2026: synergistic core +6%, book-to-bill 1.12, adjusted EBIT margin stable at 15 percent; Atellica now 70 percent of central-lab sales; growth-country business above three billion euros, growing double digits.

## Questions about Siemens Healthineers

### What does Siemens Healthineers do?

It develops, manufactures and sells imaging systems, radiotherapy and image-guided therapy equipment and in-vitro diagnostics to hospitals, laboratories and clinics in more than 180 countries.

### What was Siemens Healthineers' revenue?

FY2025 revenue (year to 30 September 2025) was €23,375 million, up 5.9% comparable, with adjusted EBIT of €3,855 million.

### How many employees does Siemens Healthineers have?

About 74,000 employees at September 30, 2025.

### What is Siemens Healthineers' strategy?

Elevating Health Globally (FY2026-FY2030) combines Patient Twinning, Precision Therapy and Healthcare AI, targeting 5-7% comparable growth a year with double-digit adjusted EPS growth.

### Who leads Siemens Healthineers?

Dr. Bernd Montag is CEO and Dr. Jochen Schmitz is CFO; both were reappointed until February 28, 2031.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
